Publication Standards for Retrospective Studies in Pharma Research

Published on 22/12/2025

How to Meet Publication Standards for Retrospective Studies in Pharma

Retrospective chart reviews and observational studies play a key role in generating real-world evidence (RWE). However, the scientific value of such studies depends heavily on their transparency and reporting rigor. Meeting publication standards ensures credibility, reproducibility, and compliance with ethical and regulatory expectations. This guide explains how pharma professionals and clinical researchers can effectively prepare retrospective study manuscripts for publication.

Table of Contents

Why Standardization Matters in Retrospective Research Publications:

Unlike randomized controlled trials (RCTs), retrospective studies are prone to bias, incomplete data, and lack of pre-specified protocols. Standardized reporting:

Enhances transparency and reproducibility
Facilitates peer review and editorial acceptance
Reduces interpretational bias and improves data credibility
Aligns with global regulatory and ethical frameworks
Supports informed healthcare decisions based on real-world GMP compliance

Several reporting guidelines exist to aid retrospective study authors in achieving these goals. The most prominent among them is the STROBE statement.

Using the STROBE Guidelines for Retrospective Chart Reviews:

The STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) checklist provides a structured framework for reporting observational research including cohort, case-control, and cross-sectional studies. For retrospective studies, key elements include:

Title and Abstract: Clearly indicate the study design, such as “Retrospective

Chart Review of X…”

Introduction: Provide the scientific background and rationale for using retrospective methodology.

Methods: Describe eligibility criteria, sources of data (e.g., EMRs vs paper charts), abstraction tools, and sampling strategy.

Bias and Confounding: State how bias was minimized, and confounding variables managed or analyzed.

Statistical Analysis: Outline how missing data, heterogeneity, or inter-rater variability were handled.

Ethics: Mention IRB approval, HIPAA compliance, and any waivers obtained.

Results: Use tables/graphs to present data with clarity. Include flow diagrams if applicable.

Discussion: Acknowledge study limitations, generalizability concerns, and potential conflicts of interest.

Funding and Transparency: Disclose sponsors, data availability, and author roles.

Templates aligned with STROBE can be found in pharma SOP documentation repositories or editorial guideline portals.

Ethical Standards for Publishing Retrospective Research:

Though retrospective studies often use existing data, they must still comply with ethical publishing standards. Ensure the following:

IRB Review: Obtain IRB approval or waiver documentation
HIPAA and GDPR Compliance: Ensure all protected health information (PHI) is properly de-identified
Conflict of Interest Declarations: Follow ICMJE conflict disclosure forms
Trial Registration: While not mandatory, registration in a database like ClinicalTrials.gov boosts transparency
GPP3 Alignment: Follow Good Publication Practice (GPP3) for authorship and sponsor involvement

Publications that fail to address these can be rejected or flagged post-publication. Refer to pharma regulatory requirements for region-specific ethical expectations.

Selecting the Right Journal for Your Retrospective Study:

Choose a journal that aligns with your therapeutic area and accepts observational study formats. Consider the following criteria:

Open access vs subscription model
Indexing in PubMed or Scopus
Focus on real-world evidence or health outcomes
Clear guidelines for STROBE or CARE adherence
Acceptance rates and publication speed

Some suitable journals include:

BMC Medical Research Methodology
Journal of Comparative Effectiveness Research
Pharmacoepidemiology and Drug Safety
BMJ Open
Value in Health

Data Transparency and Supplementary Files:

High-quality retrospective research publications include supplementary files that support transparency and reproducibility. These may include:

Study Protocol or Data Abstraction Form
Codebook for Variables
IRB Waiver Documentation
De-identified Dataset Samples
Statistical Analysis Code (e.g., R or SAS scripts)

Clearly label supplementary files and reference them in the main manuscript. This aligns with transparency guidelines and boosts acceptance probability in peer-reviewed journals.

Common Pitfalls to Avoid in Retrospective Study Publishing:

Omitting bias mitigation strategies
Using ambiguous study designs or terminology
Failing to declare ethical compliance
Not distinguishing retrospective vs prospective designs
Incomplete description of abstraction methods or inter-rater reliability

Always include details such as coding practices, data source descriptions (e.g., real-time stability studies or EMRs), and data cleaning steps.

Checklist for Publication Preparation:

[ ] Align manuscript with STROBE checklist
[ ] Include structured abstract with design, setting, and population
[ ] Detail chart abstraction and quality control methods
[ ] Disclose ethics approvals and conflict of interest
[ ] Provide funding transparency and author contributions
[ ] Format references using target journal style
[ ] Submit all supplementary materials as per submission portal

Conclusion:

Publishing retrospective chart reviews in compliance with global standards is essential to maximizing their scientific value. By following structured guidelines like STROBE, maintaining ethical rigor, and choosing suitable journals, pharma professionals can ensure their real-world research withstands peer scrutiny and contributes meaningfully to evidence-based decision-making. Transparency, consistency, and protocol adherence remain the pillars of successful retrospective study publications.

As per EMA publication guidance, retrospective data must be contextualized, standardized, and peer-reviewed to be used for regulatory insights.